EP1420747A4 - Benzochuinonansamycine - Google Patents

Benzochuinonansamycine

Info

Publication number
EP1420747A4
EP1420747A4 EP02768436A EP02768436A EP1420747A4 EP 1420747 A4 EP1420747 A4 EP 1420747A4 EP 02768436 A EP02768436 A EP 02768436A EP 02768436 A EP02768436 A EP 02768436A EP 1420747 A4 EP1420747 A4 EP 1420747A4
Authority
EP
European Patent Office
Prior art keywords
benzoquinone ansamycins
ansamycins
benzoquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02768436A
Other languages
English (en)
French (fr)
Other versions
EP1420747A2 (de
Inventor
Daniel Santi
David C Myles
Zong-Qiang Tian
C Richard Hutchinson
Robert Johnson
Yi-Qing Zhou
Li Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of EP1420747A2 publication Critical patent/EP1420747A2/de
Publication of EP1420747A4 publication Critical patent/EP1420747A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02768436A 2001-08-06 2002-08-05 Benzochuinonansamycine Withdrawn EP1420747A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US31007901P 2001-08-06 2001-08-06
US310079P 2001-08-06
US38925502P 2002-06-14 2002-06-14
US389255P 2002-06-14
US39392902P 2002-07-03 2002-07-03
US393929P 2002-07-03
US39527502P 2002-07-12 2002-07-12
US395275P 2002-07-12
PCT/US2002/024891 WO2003013430A2 (en) 2001-08-06 2002-08-05 Benzoquinone ansamycins

Publications (2)

Publication Number Publication Date
EP1420747A2 EP1420747A2 (de) 2004-05-26
EP1420747A4 true EP1420747A4 (de) 2010-06-02

Family

ID=31982570

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02768436A Withdrawn EP1420747A4 (de) 2001-08-06 2002-08-05 Benzochuinonansamycine

Country Status (3)

Country Link
EP (1) EP1420747A4 (de)
AU (1) AU2002330998A1 (de)
WO (1) WO2003013430A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189549B2 (en) * 2002-06-14 2007-03-13 Kosan Biosciences, Inc. Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthase and accessory proteins, and uses thereof
US20050002983A1 (en) * 2003-03-28 2005-01-06 Johnson Robert G. Devices, methods, and compositions to prevent restenosis
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
ES2409351T3 (es) 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
KR101374553B1 (ko) 2004-11-18 2014-03-17 신타 파마슈티칼스 코프. Ｈｓｐ90 활성을 조절하는 트리아졸 화합물
WO2007001049A1 (ja) * 2005-06-29 2007-01-04 Kyowa Hakko Kogyo Co., Ltd. ベンゼノイドアンサマイシン誘導体
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
EP2001455A2 (de) 2006-03-15 2008-12-17 Theralogics, Inc. Verfahren zur behandlung von muskelschwunderkrankungen mithilfe von hemmern der nf-kb-aktivierung
WO2007113268A1 (en) * 2006-03-31 2007-10-11 Biotica Technology Ltd. 4, 5-dihydromacbecin derivatives and their use in the treatment of cancer or b-cell malignancies.
GB0606542D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
EP2073807A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
ES2347619B1 (es) * 2008-05-13 2011-09-15 Consejo Superior De Investigaciones Cientificas (Csic) (50%) Procedimiento para diseñar una terapia individual antitumoral basado en la deteccion de los niveles de proteina hsp90, el uso de inhibidores de la proteina hsp90 para la elaboracion de composiciones farmaceuticas, las composiciones asi obtenidas y sus aplicaciones.
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
CN112679374A (zh) * 2021-01-12 2021-04-20 湖南复瑞生物医药技术有限责任公司 2-氟-6-(三氟甲基)苯甲酰胺的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111419A (en) * 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111419A (en) * 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1981, XP002577770, retrieved from STN Database accession no. 1981:71490 *
Z. LIAO E T AL, ACTA PHARMACEUTICA SINICA, vol. 36, no. 8, August 2001 (2001-08-01), pages 569 - 575, XP008045475 *

Also Published As

Publication number Publication date
WO2003013430A2 (en) 2003-02-20
WO2003013430A3 (en) 2004-03-04
AU2002330998A1 (en) 2003-02-24
EP1420747A2 (de) 2004-05-26

Similar Documents

Publication Publication Date Title
EP1420747A4 (de) Benzochuinonansamycine
DE50202400D1 (en) Baw-resonator
DE60237965D1 (en) Metalloproteinaseinhibitoren
DE60234996D1 (en) Photovervielfacher
GB0227332D0 (en) Mailer-ID
DE50214962D1 (en) Heterocyclylarylsulfonamide
GB0125051D0 (en) GT speedlock
GB0112053D0 (en) Bacsac
CA93647S (en) Fauteuil
CA93075S (en) Travelbag
GB0126335D0 (en) Letters
AU143674S (en) An aquafoil
PL112803U1 (en) Section
AU146628S (en) Section
PL112804U1 (en) Section
AU149609S (en) Section
PL112794U1 (en) Section
PL112800U1 (en) Section
PL112801U1 (en) Section
PL112802U1 (en) Section
AU146768S (en) Section
PL111856U1 (en) Advertisement rack
PL112103U1 (en) Advertisement rack
GB0210130D0 (en) Rotavators
GR2002341Y (en) Euroconverter

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/395 20060101ALI20100420BHEP

Ipc: C07D 491/08 20060101ALI20100420BHEP

Ipc: C07D 225/06 20060101AFI20100420BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100506

17Q First examination report despatched

Effective date: 20101228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150703